Intellia Therapeutics (0JBU) Ratios
7 Followers
Intellia Therapeutics Ratios
GB:0JBU's free cash flow for Q2 2026 was $-84.92M. For the 2026 fiscal year, GB:0JBU's free cash flow was decreased by $-1.81M and operating cash flow was $-83.11M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.08 | 5.77 | 8.67 | 9.61 | 6.11 |
| Quick Ratio | 5.08 | 5.77 | 8.67 | 9.61 | 6.11 |
| Cash Ratio | 1.50 | 1.71 | 1.97 | 4.14 | 0.98 |
| Solvency Ratio | -2.32 | -1.59 | -1.88 | -1.64 | -1.03 |
| Operating Cash Flow Ratio | -3.36 | -3.15 | -3.42 | -2.63 | -1.79 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 356.98M | $ 320.80M | $ 747.52M | $ 932.27M | $ 515.08M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.11 | 0.18 | 0.09 | 0.09 | 0.06 |
| Debt-to-Equity Ratio | 0.14 | 0.24 | 0.11 | 0.11 | 0.07 |
| Debt-to-Capital Ratio | 0.12 | 0.19 | 0.10 | 0.10 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.25 | 1.37 | 1.24 | 1.23 | 1.24 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.86 | 2.13 | 1.30 | 1.70 | 1.04 |
| Net Debt to EBITDA | 0.16 | -0.04 | 0.22 | 0.87 | 0.19 |
| Profitability Margins | |||||
| Gross Profit Margin | 76.47% | 82.23% | 75.26% | 85.47% | 79.15% |
| EBIT Margin | -609.85% | -896.77% | -1420.51% | -879.04% | -810.37% |
| EBITDA Margin | -586.32% | -879.00% | -1395.77% | -864.51% | -789.52% |
| Operating Profit Margin | -651.67% | -923.10% | -1420.51% | -879.04% | -810.37% |
| Pretax Profit Margin | -609.85% | -896.77% | -1326.51% | -909.78% | -810.49% |
| Net Profit Margin | -609.85% | -896.77% | -1326.51% | -909.78% | -810.49% |
| Continuous Operations Profit Margin | -609.85% | -896.77% | -1326.51% | -909.78% | -810.49% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 93.58% | 97.15% | 93.38% | 103.50% | 100.02% |
| Return on Assets (ROA) | -49.01% | -43.58% | -36.99% | -31.19% | -20.70% |
| Return on Equity (ROE) | -61.47% | -59.52% | -45.82% | -38.38% | -25.75% |
| Return on Capital Employed (ROCE) | -59.74% | -49.46% | -43.46% | -32.88% | -22.92% |
| Return on Invested Capital (ROIC) | -57.67% | -48.55% | -42.79% | -32.49% | -22.74% |
| Return on Tangible Assets | -49.01% | -43.58% | -36.99% | -31.19% | -20.70% |
| Earnings Yield | -42.36% | -45.03% | -17.78% | -17.66% | -3.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.15 | 6.80 | 1.00 | 13.83 | 16.27 |
| Payables Turnover | 0.79 | 0.70 | 1.20 | 1.47 | 0.71 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.55 | 0.23 | 0.24 | 0.32 | 0.33 |
| Asset Turnover | 0.08 | 0.05 | 0.03 | 0.03 | 0.03 |
| Working Capital Turnover Ratio | 0.14 | 0.08 | 0.04 | 0.06 | 0.06 |
| Cash Conversion Cycle | -413.16 | -464.03 | 63.79 | -222.06 | -488.87 |
| Days of Sales Outstanding | 51.07 | 53.71 | 366.82 | 26.39 | 22.43 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 464.23 | 517.74 | 303.03 | 248.44 | 511.30 |
| Operating Cycle | 51.07 | 53.71 | 366.82 | 26.39 | 22.43 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.22 | -3.53 | -4.44 | -4.33 | -3.17 |
| Free Cash Flow Per Share | -3.27 | -3.59 | -4.60 | -5.09 | -3.35 |
| Dividend Paid and CapEx Coverage Ratio | -60.38 | -60.38 | -28.18 | -5.71 | -17.64 |
| Capital Expenditure Coverage Ratio | -60.38 | -60.38 | -28.18 | -5.71 | -17.64 |
| Operating Cash Flow Coverage Ratio | -3.74 | -1.66 | -3.42 | -2.55 | -3.04 |
| Operating Cash Flow to Sales Ratio | -5.16 | -6.03 | -10.86 | -6.39 | -6.81 |
| Free Cash Flow Yield | -36.40% | -30.77% | -15.08% | -14.58% | -2.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.36 | -2.22 | -5.62 | -5.66 | -31.29 |
| Price-to-Sales (P/S) Ratio | 14.40 | 19.91 | 74.61 | 51.53 | 253.61 |
| Price-to-Book (P/B) Ratio | 1.45 | 1.32 | 2.58 | 2.17 | 8.06 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.75 | -3.25 | -6.63 | -6.86 | -35.25 |
| Price-to-Operating Cash Flow Ratio | -2.79 | -3.30 | -6.87 | -8.06 | -37.25 |
| Price-to-Earnings Growth (PEG) Ratio | 0.09 | 0.71 | 0.47 | -0.09 | -0.54 |
| Enterprise Value Multiple | -2.30 | -2.31 | -5.13 | -5.09 | -31.93 |
| Enterprise Value | 912.17M | 1.17B | 2.60B | 2.29B | 8.33B |
| EV to EBITDA | -2.30 | -2.31 | -5.13 | -5.09 | -31.93 |
| EV to Sales | 13.48 | 20.28 | 71.54 | 43.99 | 252.11 |
| EV to Free Cash Flow | -2.57 | -3.31 | -6.36 | -5.85 | -35.04 |
| EV to Operating Cash Flow | -2.61 | -3.36 | -6.59 | -6.88 | -37.03 |
| Tangible Book Value Per Share | 6.20 | 8.82 | 11.83 | 16.05 | 14.67 |
| Shareholders’ Equity Per Share | 6.20 | 8.82 | 11.83 | 16.05 | 14.67 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.62 | 0.59 | 0.41 | 0.68 | 0.47 |
| Net Income Per Share | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.93 | 1.03 | 1.00 |
| Research & Development to Revenue | 5.75 | 8.06 | 11.99 | 8.06 | 6.95 |
| SG&A to Revenue | 1.77 | 2.17 | 3.21 | 1.73 | 2.15 |
| Stock-Based Compensation to Revenue | 2.28 | 2.67 | 3.70 | 1.75 | 1.42 |
| Income Quality | 0.67 | 0.67 | 0.82 | 0.70 | 0.84 |
Currency in USD
